Giampaolo Bianchini
@BianchiniGP
Followers
2,313
Following
312
Media
55
Statuses
2,034
Head Breast Cancer Group; Head translational and immunotherapy research group; San Raffaele Scientific Institute, Milan, Italy; #PrecisionImmunology
Milano, Lombardia
Joined July 2021
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Bronx
• 613384 Tweets
Porto Alegre
• 108509 Tweets
Olmedo
• 82137 Tweets
RPWP TODAY
• 58492 Tweets
#虎に翼
• 54531 Tweets
ISABELLE NO PODDELAS
• 48451 Tweets
Bobby
• 46303 Tweets
新時代の扉
• 40371 Tweets
Tatum
• 37391 Tweets
#911onABC
• 29871 Tweets
SÃO JUÃO JULIETTE
• 29415 Tweets
Angel Reese
• 27616 Tweets
Rock in Rio
• 27488 Tweets
Bahia
• 27300 Tweets
#あさイチ
• 18562 Tweets
#VoleiNoSportv
• 15561 Tweets
OUÇA CHAVE
• 13092 Tweets
南くんの恋人
• 12759 Tweets
スタライ
• 12551 Tweets
優三さん
• 11995 Tweets
Pinned Tweet
📢1/10 Out on
@Nature
our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ lead by
@HRazaAliLab
and myself
👉To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context
🧵👇
21
110
371
📢Proud to present our manuscript 'Treatment landscape of triple-negative breast cancer — expanded options, evolving needs' which has just been published with
@SpringerNature
in
@NatRevClinOncol
If you are intrested read here:
#bcsm
#TNBC
@OncoAlert
21
213
561
📢 Potential misleading interpretation of Progression-Free Survival (PFS) (as primary endpoint) in cancer drug trials
Incredibly well written also for who is naive in trial methodology.
Take the time to read it!
You will not regret
@JAMAOnc
8
58
178
📢Proud to see our work just published in
@CCC_AACR
. Resistance to drugs targeting ER (fulvestrant) and HER2 (trastuzumab+/-pertuzumab) can be bypassed by co-targeting CDK4/6 (palbocilib), enhancing transition from quiescence to sustained senescence
👇👇
5
38
141
Senescent cell has been recently recognized as an hallmark of cancer.
#Senescence
can be exploited therapeutically, and this very well written review describe how.
@NatureRevCancer
1
39
107
📢 Improving liquid biopsy?
Terrific review describing key advances in multi-omics liquid biopsy approaches and how ‘nano-omics’, using nanotechnology tools, improves results by enriching for analytes isolation
@NatRevClinOncol
@OncoAlert
0
30
96
Optimal diagnostic/therapeutic choices in advanced
#TNBC
is critical, but many relevant clinical questions are unanswered
Here a consensus in collaboration with many Italian friends attempting to provide useful indications, including uncertain issues
1
34
90
Targeting cancer
#metabolism
in the era of
#precisiononcology
Amazing review on a very promising field of new cancer therapies.
Interested in metabolism and cancer? Don’t miss this piece of work❗️
@NaturePortfolio
@OncoAlert
3
40
90
📢POLE proofreading deficiency represents a novel agnostic biomarker for response to PD-1 checkpoint blockade therapy
Really an elegant work!
@CD_AACR
@OncoAlert
#precisionimmunology
0
28
88
📢 Do you want to reduce risks of death from all causes and cancer related for your cancer survivors patients?
👉Tell them to stay active‼️
👉Check during your visit, if they actually do physical activity
👉If not, tell them again‼️
@OncoAlert
3
38
84
📢 Intratumor
#HER2
heterogeneity matter❗️
#Heterogeneity
is a strong predictor of resistance to T-DM1 probably due to the limited bystander effect.
I expect that T-DXd would have been effective also in these cases.
#bcsm
@OncoAlert
2
18
79
Very proud and delighted to see our manuscript 'Treatment landscape of triple-negative breast cancer — expanded options, evolving needs' ranked 3rd among the most popular article published in the prestigious
@NatRevClinOncol
in 2021❗️
Interested?👉
The 3rd most popular long article published in
@NatRevClinOncol
in 2021 discusses the treatment landscape for triple negative breast cancer
0
32
112
4
10
78
🔥 Do you agree that antibody-drug conjugates (
#ADCs
) are a therapeutic revolution?
Do you know which are the most promising ADC targets in each tumor type?
If you believe ADCs are the current transformative wave in oncology, you cannot miss our last work
Thread 👇👇👇👇
🧵 1/10 🔬 Out on European Journal Of Cancer “Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response” DOI:…
If you want to know more about ADCs 👇👇👇
3
21
68
0
19
79
📢📢❗️Use of
#ctDNA
for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability | FDA
Very important initiative from FDA for moving ctDNA to the clinic (through drug development) in early stage solid tumor
@OncoAlert
1
30
71
How stratify risk of breast cancer recurrence after neoadjuvant therapy?
You should use the “Residual Cancer Burden” (RCB) (ask your pathologist to have it done)
Why I say so? Read this study and you’ll find out
#bcsm
@OncoAlert
1
17
62
What about the new category of ER Low (HER2-) breast cancer (ASCO CAP definition, ER 1-9%)? Another nice work suggested they could be regarded and treated similarly to
#TNBC
@Annals_Oncology
@OncoAlert
#bcsm
4
34
62
📢An essential must-read for anyone working in, or interested in,
#PrecisionImmunology
❗️
A comprehensive overview of computational approaches available to analyse bulk tissue and single-cell sequencing data to improve patient outcomes
@NatRevClinOncol
1
15
61
📢Terrific insights from the pan-cancer genomic characterization of 25.000 metastasis
👉differences primary vs metastasis
👉chromosomal instability correlates with metastatic burden (cancer type dependent)
👉organotropism associated with genomic features
0
16
60
📢TNBC micro-environment
Source of heterogeneity:
1) amount of cells (e.g sTILs)
2) type of cells (e.g CD8, CD4, B cell)
3) functional status of cells (e.g M1 vs M2)
4)❗️spatial distribution of cells❗️
Next step: integration of all these 4 features in a TNBC ecosystem landscape
The
#TNBC
immune microenvironment is not just ‘hot’ or ‘cold’ - distinct excluded, ignored and inflamed phenotypes w distinct ICI responses.
Spatial profiling is coming!
@NatureComms
#bcsm
@OncoAlert
1
38
130
2
17
57
#BrainMetastases
from solid tumors remain a major unmet need. More research and dedicated trials are needed, but - to provide the best available treatment - look at
@EANOassociation
@myESMO
#GUIDELINES
2
18
56
📢DB03 out on NEJM.
This is a big jump in the history of cancer.
Indeed, it is far beyond having an incredibly effective drug (Trastuzumab Deruxtecan) available in early lines of BC.
This is more about how ADCs could be transformative in cancer treatment
0
11
55
Predicting risk of developing severe immune-related adverse events (irAEs) by liquid biopsy!
An important contribution to
#PrecisionImmunology
@NatureMedicine
1
7
50
📢 How tumour
#heterogeneity
shapes drug resistance and sensitivity by Darwinian selection under therapeutic pressure❓
Very important topic
Don’t miss this review, if you are interested in
@APassaroMD
0
8
47
#ESMO21
1/10📢MONALEESA-2 impressive results but who benefits the most and who do not benefit enough?
An answar to this question in e-Poster 292P
Great team work on BioItaLEE trial
@LMalorni
@puglisi_fabio
@FilippoMontemu1
@delmastro_lucia
@GraziaArpino
Here a summary👇👇
2
15
47
It is worthy to mention that this is the results of the efforts made by many Italian investigators and by a super steering committee of friends.
Great 🇮🇹 team work!
@LMalorni
@grazia_arpino
@puglisi_fabio
@delmastro_lucia
@FilippoMontemu1
@mauricallari
General session 3 at
#SABCS21
: super 2nd oral presentation by the great
@BianchiniGP
of
#BioItaLEE
trial showing prognostic value and dynamics of
#ctDNA
in
#HR
+/
#HER2
- advanced
#BreastCancer
patients treated with 1st line
#ribociclib
and
#letrozole
@OncoAlert
#bcsm
#ItalianPride
0
12
36
0
11
44
📢 Amazing deep diving into essential immunologic concepts underpinning natural immunity and highlight challenges faced by cancer vaccines
Key point
👉 antigen selection & delivery
👉 monitoring of post-vaccination responses
👉 novel approaches
0
15
44
1/3 Totally agree
@PTarantinoMD
The “no need of imaging/markers for surveillance in breast cancer” is one of the most questionable dogma. This is based on two randomized studies published on JAMA in 1994
31 more drugs (31) approved by FDA and/or EMA after 1994 for BC
👇👇👇👇
Interesting
@JNCI_Now
article challenging a fossilized dogma. Authors followed a stage-stratified random sample of 10.000 women w/ stage II-III BC for 10 yrs, finding an improvement in OS for surveillance imaging among TNBC & HER2+ (but not HR+/HER2-) 1/2
9
40
120
5
13
44
Read our latest
#review
on
#TNBC
, published with
@SpringerNature
in
@NatRevClinOncol
More than 140
#immunotherapy
trials testing immune combinations. Too much of good things? Where we are in precision immunology? Adjuvant or neoadjuvant?
👉
#bcsm
A Review in
@NatRevClinOncol
describes the current and upcoming therapeutic landscape of triple-negative breast cancer.
0
17
58
4
12
41
Tumor Mutational Burden (TMB) analytical issues matter to improve
#PrecisionOncology
A software tool developed and made publicly available to promote reproducibility and comparability across assays
@Annals_Oncology
@OncoAlert
0
19
39
📢This study describes clonal
#heterogeneity
at unprecedented levels.
Capturing spatially resolved DNA sequences from intact tissue sections authors show that clonal populations are confined to distinct spatial regions.
@Nature
0
8
39
🔥 ER+/HER2- is highly heterogeneous “one size does not fit all”
👉Benefit from endocrine (+/- CDK4/6) and chemo/immunotherapy therapies are driven by different molecular features‼️
Key contribution to
#PrecisionImmunology
in BC
Don’t miss our work just out
Thread 👇👇👇
📢1/8 A subset of ER+/HER2-
#breastcancer
may benefit from
#immunotherapy
, but which tumors are these?🤔
Our latest study just out on
@BrJCancer
@SpringerNature
sheds light on this highly relevant topic
Read more:📌
@BianchiniGP
@mauricallari
1
6
24
0
11
39
📢 Gut microbiome has been associated with immune checkpoints benefit and toxicity.
In this great pice of work on
@NatureMedicine
, authors correlates
#microbiome
to response and toxicity following anti-CD19 CAR T cell therapy.
0
12
37
🔥 Delighted to see in this week’s issue on
@Nature
our work describing ‘Spatial predictors of immunotherapy response in triple-negative breast cancer” and honored to see our work covered in the Nature Briefing
@SpringerNature
@HRazaAliLab
Thread 👇👇👇👇
📢1/10 Out on
@Nature
our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ lead by
@HRazaAliLab
and myself
👉To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context
🧵👇
21
110
371
0
8
38
#Hypoxia
is known to drive resistance to chemotherapy, targeted therapy and immunotherapy. Can hypoxia be therapeutically exploited? Don’t miss this review, if you wanna know.
@NatRevClinOncol
0
12
38
#Fasting
-mimicking diet (FMD) is safe and reshapes
#metabolism
and antitumor immunity in
#cancer
patients.
Eagerly awaited results of an important study which pave the way for the clinical implementation of FMD.
Congratulations to Claudio and co-authors!!
0
6
38
📢ctDNA in breast cancer: not so far from prime time
Wonderful summary of great data presented at
@SABCSSanAntonio
including our BioItaLEE study which I was honored to present
@LMalorni
@grazia_arpino
@delmastro_lucia
@puglisi_fabio
@FilippoMontemu1
Researchers at
@SABCS2021
described new ways physicians can use fragments of tumor DNA found in patients’ blood to guide treatment decisions. Learn more on the
#AACRBlog
:
@PedramRazaviMD
@BianchiniGP
0
7
11
0
14
34
📢Therapeutic resistance to anti-oestrogen therapy in breast cancer.
How breast cancers evolve under the pressure of anti-oestrogen therapy?
If you wanna know, don’t miss this terrific review
#bcsm
@OncoAlert
1
15
35
About obesity and cancer
You may be surprised to learn that being overweight or having obesity are linked with a higher risk of getting 13 types of cancer. These cancers make up 40% of all cancers diagnosed in the US each year. Not all are caused by obesity, but it plays a role.
1
35
49
1
12
34
📢 Mechanism of most common chemotherapy related acute toxicities and their optimal management
Such an important topic ❗️
Don’t miss this great pice of work by
@NicoleKuderer
and others.
@NatRevClinOncol
@OncoAlert
In a Review now online,
@NicoleKuderer
,
@ADesaiMD
,
@maryam_lustberg
and
@gary_lyman
explain the most common acute toxicities in patients with cancer receiving chemotherapy and discuss management options:
19
292
630
1
10
33
#ESMO21
Pembrolizumb/CT will be the new standard in high-risk TNBC. Well… but does one size fits all?
#PrecisionImmumology
is a major unmet need
Find out more on LBA12 and read the today Daily Reporter
@myESMO
@mauricallari
#Immuno
-oncology score predicts response to atezolizumab in
#TNBC
: Results from an exploratory post-hoc analysis of the NeoTRIPaPDL1 study 👉
#ESMO21
Daily Reporter
#bcsm
#breastcancer
#immunotherapy
#tcell
0
9
19
1
12
32
📢Which is the risk of ‘very late’ breast cancer recurrence?
This study investigated the risk of BC
#recurrence
10 years up to 32 (❗️) years after primary BC diagnosis.
#bcsm
#laterecurrence
@OncoAlert
1
7
33
Monarch 2 IA2 OS results
They did not reach the boundary for statistical significance
My opinion (and interpretation): a clinical meaningful improvement in OS! In abemaciclib arm 67.1 median OS
Impressive data (despite immature)
At 5 years 17.3% more patients free of progression
3
10
33
📢 Another piece of evidence on the importance (and impact) of Breast Cancer
#screening
programs for women age 40-49 years
👉 in this study translate into a significant 10-Year net survival benefit
#bcsm
0
16
33
Our contribution to
#PrecisionImmunology
in TNBC at
@SABCSSanAntonio
GS1-00 Imaging mass cytometry
PD10-06 Predictive value of DetermaIO
PD10-09 Immune modulation by anthracyclines and taxanes
P1-04-02 Biology of PD-L1 dynamic
P2-07-12 IO score and TNBC dynamic
#SABCS21
2
9
31
Should we adopt the curative-intent treatment strategy used for locally advanced breast cancer in oligometastatic disease?
This compelling question is thoughtfully explored in this commentary, and it is time to test this hypothesis in clinical trials
0
11
32
Totally agree with
@prat_aleix
This is critical issue for the advancement of medical research.
Be a physician-scientists is a so fascinating and exciting career. Actions are needed starting from education, mentoring and hospitals organization. Motivation and passion are key.
I am really worried about the lack of physician-scientists in Spain and other countries
Translating science to medicine: The case for physician-scientists
@ScienceMagazine
@ASEICAnews
@_SEOM
4
28
96
2
4
31
Impressive results for Patritumab Deruxtecan (
#ADC
targeting HER3) for EGFR+ NSCLC.
This compound is extremely promising across several histologies (including breast cancer)
0
2
31
The extracellular matrix (ECM) contributes to “immune exclusion” which predicts
#resistance
to
#immunotherapy
, including
#TNBC
Preclinical findings suggest a target (DDR1) for increasing immune accessibility through reconfiguration of the tumour ECM
#bcsm
0
4
29
📢Elacetrant approval for ESR1-mutated ER+ aBC
MUCH MORE than just a new treatment option in BC
It means
👉 A new ESCAT "tier I-A" molecular alteration in BC
👉 Define a key role of liquid biopsy for target detection
And what about ESR1 wt?
@OncoAlert
2
6
27
Great news
@hoperugo
❗️
Sacituzumab Govitecan significantly improve OS also in HR+/HER2- BC (second IA TROPICS 2) (third to fifth line)
Urgently needed data of SC after T-DXd in HER2low (T-DXd will be mostly used in second line)
#bcsm
@OncoAlert
Second interim analysis shows significant OS benefit! Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study.
@OncoAlert
1
40
140
0
4
27
#ADC
in HER2+ cancers
Unprecedented results of T-DXd in breast cancer and many other solid tumors set the bar of expectation from ADCs at a very high level
Stay tuned because this is only a tip of an iceberg
#bcsm
@OncoAlert
ARX788 is an ADC that combines a HER2-directed monoclonal antibody with Amberstatin269, which can destroy cancer cells and prevent new cell growth.
@KeckMedUSC
#bcsm
#oncology
0
5
13
1
10
29
Summary SERD
- EMERALD phase 3 n=466, POS trial, benefit driven by ESR1-mut (co-primary end point)
- acelERA phase 2 n=303, press release NEG
- AMEERA-3 phase 2 n=367, press release NEG
Comment
- waiting for the data
- NEG does’t mean no effect
- ESR1-mut matter
- Smaller size
Giredestrant did not meet the primary endpoint of improving PFS in the randomized phase 2 acelERA trial.
9
25
50
0
5
29
📢🔥 Positive results from TROPION-Breast01‼️
Datopotamab Deruxtecan (ADC TROP2-directed) significantly ⬆️⬆️ PFS (and a trend for ⬆️ OS) compared to chemotherapy in ER+/HER2- BC
Wonderful! Third ADCs 👏
Next: define optimal selection and sequencing
0
11
27
1
1
28
Lessons learnt and remaining questions after GepardNuevo results, discussed in our editorial on
@Annals_Oncology
Some topics
👉 are results practice changing?
👉 role of ICI after surgery?
👉 is quality of pCR different after ICI?
👉 how to deal with residual disease?
@OncoAlert
Chemo + immunotherapy has become the SoC in the neoadjuvant setting of early TNBC. In this Editorial accompanying the GeparNuevo trial results,
@BianchiniGP
and coll. provide presepctives on lessons learnt and remaining questions.
➡️
#bcsm
0
14
16
0
13
27
#Microbiome
causally impact
#cancer
and treatment responsiveness.
Another great review, you should not miss if you are interested to know more about this fascinating topic.
0
4
26
🔥More gems from our
@Nature
paper
🔍intracellular carboplatin increasingly accumulate during therapy, expecially in macrophages
🔍T cells in direct contact with cancer cells were functionally distinct:⬆️activation markers TOX, PD-1, OX40 and⬆️proliferating
See also thread👇👇
📢1/10 Out on
@Nature
our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ lead by
@HRazaAliLab
and myself
👉To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context
🧵👇
21
110
371
1
9
26
Proper biomarker validation is frequently missing, so many findings in the literature are false positive results.
In this study in >3700 pts germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across several solid tumor types.
0
8
25
📢❗️FDA approval of adjuvant
#Abemaciclib
in high-risk HR+ HER2- eBC: a treatment revolution
Next question will be:
- Who is already cured by endocrine therapy alone?
- Who relapse despite this combination?
#PrecisionOncology
is not “one size fits all”
#bcsm
0
8
25
📢Fatty Acid metabolism, mediated by CD36, dictate worse outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapies (NeoALTTO & NeoSphere)
👉highlight the relevance of cancer metabolism in BC
Glad to have contributed
#bcsm
1
7
25
🐓 or 🥚, who comes first?
#Immunoediting
:
#clonal
selection of recurrent mutations in tumor suppressor genes is driven largely by the tumor’s requirement to avoid the adaptive immune system.
Fantastic piece of work!
@ScienceMagazine
0
7
25
📢 Very interesting work on
@Nature
suggesting a new link between the stress-associated catecholamines and the progression of T cell exhaustion
IMPLICATION 👉 blocking β-adrenergic signalling in CD8+ T cells MIGHT rejuvenates anti-tumour functions
0
8
26
📢 Patients’ sex influence the efficacy and toxicity of immune checkpoint inhibitors in solid tumors!
This is due to a complex interaction among hormones, genes, behaviors, and the microbiome that affects both innate and adaptive immune functions
0
8
23
📢Trastuzumab Deruxtecan a tremendously effective blockbuster drug demand an optimal management to maximize benefits
👉prophylaxis of nausea/vomiting
👉early detection and management of ILD
👉other AEs
Interested?
Don’t miss this pice of work done with
@hoperugo
@JavierCortesMD
Now on line right after the historic FDA approval of T-DXd for HER2low MBC: Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer - ScienceDirect
@OncoAlert
0
33
89
1
6
22
ASCO
#guidelines
faster than FDA on
#adjuvant
#Olaparib
in patients with high-risk HER2-neg BC and gBRCAmut. Such transformative data deserve faster tracks of regulatory approval. Welcomed
@ASCO
initiative
0
8
24
#ESMO21
MONALEESA-2 OS results
👉12.5 months improvement
👉 63 months median OS with ribociclib/AI
This is the longest median OS never reported in a clinical trial in
#bcsm
Amazing!
Is it not the time to ask for OS as primary (or co-primary) endpoint of clinical trials?
@myESMO
...finally at
#ESMO21
median overall survival of patients with metastatic
#HormoneReceptor
-positive/
#HER2
-negative
#BreastCancer
is reported to exceed 5 years in a
#RCT
...still a lot of work to do for curing these patients but this is a very important result!
@OncoAlert
@myESMO
2
39
136
0
8
22
📢
#Response
,
#resistance
, and
#toxicity
to
#immunecheckpoint
blockade: which are the
#hallmarks
?
Terrific overview, don’t miss it!
@MDAndersonNews
@OncoAlert
@JenWargoMD
0
1
22
📢Intrested in
#precisionimmunology
in breast cancer?
Check out our review in
@TheBreastOnline
about tissue and liquid biopsy based biomarkers for immunotherapy benefit/resistance
Tailoring immunotherapy is a high unmet need
Great work
@LLicata88
@f_rossari
@Marco52630700
💥Proud to present my first "co-first" manuscript "Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer" which has been just published in
@TheBreastOnline
. 💥
@BianchiniGP
@LLicata88
@f_rossari
1
13
27
0
13
22
📢 The deadly spread of breast cancer through spontaneous CTC intravasation occurs predominantly during sleep❗️
Really fascinating work
Circadian rhythm hormones dictate CTC generation dynamics
This provide the rationale for time-controlled treatments
1
10
22
🔥Very important: All imaging mass cytometry and clinical response data can be accessed via a Zenodo data repository () for academic, non-commercial research!
A terrific resource for the scientific community to build upon our findings
4
3
22
📢Sonifi discontinued all ongoing studies with amcenestrant after negative results of AMEERA-5 trial
This decision will impact others SERD development programs
My opinon 👉 SERD are game changer for ESR1 mutated tumors
Who may also benefit the most?
2
11
20
Great news for high-risk
#TNBC
:
👉
#BrighTNess
trial reinforced data suggesting the benefit of adding
#carboplatin
to anthracycline-taxane based therapy
👉
#pembrolizumab
add to a carbo/taxane/anthracycline based regimen
But could we de-escalate for some?
#bcsm
Wow - impressive EFS benefit of adding carboplatin to NACT for TNBC in
#BrighTNess
trial!
👉4-year EFS was 79% with carbo vs 68% w/o (HR 0.57, p=0.02)
Just released by
@myESMO
Daily Reporter, these data will be presented by S.Loibl on 17 Sept @
#ESMO21
10
63
151
1
6
21
@DocMCotant
@SidYadavMD
@PTarantinoMD
Are you intrested in more information about optimal management of nausea/vomiting by T-DXd?
I would recommend this very useful and practical manuscript written with
@hoperugo
@JavierCortesMD
and other colleagues
1
5
21
😂🤣😂🤣
0
2
20
#Radiomics
and
#Artificial
Intelligence might revolutionize how we “look at” cancer, providing unprecedented level of information on biology, prognosis, and precisely predicting treatment benefit
Don’t miss this perspective
@NatRevClinOncol
0
8
20
#ESMO21
Thank you
@myESMO
for this step towards the normality.
Science is not just a matter of number and data, it is the result of passion, dedication, creativity, engagement and friendship…. we need to see it in each other face!
Happy to come back to life
#ESMO21
📸Great opportunity to catch up with the amazing
@myESMO
#breastcancer
faculty and community
Honored and happy to meet all these inspiring people in person
@OncoAlert
@myESMO
#bcsm
4
9
64
1
2
20
Vuoi rendere il cancro sempre più curabile?
C’è una sola strada: la
#RICERCA
Sostieni
#AIRC
❗️
Sostieni migliaia di ricercatori come me. Noi mettiamo passione e dedizione. Tu scendi in campo insieme a noi.
GRAZIE del TUO contributo!
@RaiDue
@AIRC_it
#CheckUp
#RAIperAIRC
#bcsm
Per parlare dei progressi nel campo della ricerca sul tumore al seno, a
#CheckUp
è intervenuto il Dott. Bianchini, ricercatore
@AIRC_it
💪
➡ #ÈQuestoIlMomento di sostenere con decisione la ricerca. Dona al 45521 o sul sito ❤️
#AIRC
#RAIperAIRC
❤️
2
6
17
1
4
19
Please, do not forget to talk with your patients about the benefit of physical activity. No side effects
Success guaranteed❗️
#bcsm
0
3
19
📢Very interesting finding!
Histamine and histamine receptor H1 confer
#resistance
to
#immunotherapy
, also in human (through M2-like polarization)
Warrant exploring antihistamines as adjuvant agents for combinatorial immunotherapy
1
5
18
📢Do you think that lymph nodes involvement dictate poor prognosis because of a higher disease burden and tumor propensity for metastastatic spread?
If so, you must read this pice of work‼️
Nodes colonization promotes metastasis by inducing broad alterations in tumor immunity
Tumors spread to lymph nodes before they metastasize to distant tissues, but for over a century scientists have debated whether this matters. It does. Check out our paper online now
@CellCellPress
@CellPressNews
1/15
43
527
2K
0
3
19
📢📢No doubts: take the third dose of COVID-19 vaccine as soon as possible (and as soon as indicated)❗️
I got it last Friday😉
0
8
19
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition
This is a very nice summary of our work!
👉CDK4/6 inhibitors may be effective also in HER2+ BC
#bcsm
@OncoAlert
0
3
19
📢Are we using
#PARPi
in advanced breast cancer in the only (and the best) possible way?
#Maintenance
after platinum-based chemo is a poorly investigated approach.
In BROCADE3, an exploratory evaluation of Veliparib after CT show compelling results.
#bcsm
0
5
18
#ESMO21
: CDK4/6 inhibitors have led to a paradigm shift in the treatment of HR-positive/HER2-negative
#aBC
, offering patients the opportunity to live significantly longer and better lives. Editorial by
@CarmenCriscit
👉
#bcsm
#advancedbreastcancer
1
15
41
0
5
18
1/2
#ESMO21
📢 📢
#Pembrolizumab
improved OS (6.9 months❗️) in first line TNBC and PD-L1 CPS >10 (Dako 22C3)
It also increased PFS, ORR, duration of response, without new safety signal
Great news for
#TNBC
pts
@myESMO
#bcsm
My considerations below
👇👇👇
Oral abstract session on advanced
#BreastCancer
at
#ESMO21
: presented by
@hoperugo
updated results from
#KEYNOTE355
trial showing significant
#OS
benefit with addition of
#pembrolizumab
to
#chemotherapy
in
#TNBC
patients with
#PDL1
pos (CPS >=10) disease
@OncoAlert
@myESMO
#bcsm
0
12
50
1
5
18
📢 Historical step: first oral fecal microbiota transplant therapy approved by FDA (for recurrent Clostridioides difficile infection)
Implications 👉Pave the way for broader clinical applicability such as boosting immunotherapy benefit for cancer patients
0
5
18
🧵2/10
Immune checkpoint blockade (ICB) improves
#TNBC
outcome in both metastatic and early setting (), but biological determinants of individual benefit, especially in early setting, are unknown
Precision immunology in breast cancer is a major unmet need
2
3
18
Do you think to know everything about Estrogen Receptor (ERα) in breast cancer?
Maybe you don’t.
ERα is a potent non-canonical RNA-binding protein sustaining tumor cell survival and drug
#resistance
#bcsm
0
2
17
Nice work
@vitti10
@GaiaGriguolo
I am wondering whether these differences are a true evolution of the “molecular phenotype” or if they could be largely explain by intra-tumor heterogeneity (core biopsy # surgical samples) and pre- and post-analytical factors
#ESMO21
📢
#ESMO21
E-poster: "HER2-low breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment" by Dr. Miglietta
@vitti10
@GaiaGriguolo
HER2-low expression showed high instability from primary BC to RD after neoadjuvant treatment
0
18
45
2
3
18
🔍Which data are missing to establish Antibody Drug Conjugates (ADCs) as a transformative therapy across tumor histologies and targets?
Don't miss this great editoraial from
@FAndreMD
@BarbaraPistill2
adressing this key question
@Annals_Oncology
👇👇
0
8
17
Great overview of a decade of achievements in breast cancer research leading to 30 new indications approved by FDA.
Impressive❗️
Trust in (good) science, and science will pay you back!
#bcsm
@OncoAlert
0
6
18
Neoadjuvant
#immunotherapy
new standard of care in high-risk
#TNBC
. Now we need:
📌 Education of breast oncologist on irAE
📌 Biomarkers for
#precisionimmunology
: who do well with chemo alone? Who benefit from chemo/immuno? Who need other combinations or different drugs?
#bcsm
Immunotherapy can be considered the new standard of care in early stage TNBC
#bcsm
@myESMO
@BianchiniGP
1
17
91
0
4
15
🧵(6/10)
At baseline (pre-treatment), the presence of proliferating tumour cells expressing MHC-I and II and proliferating CD8 T cells expressing TCF1 were strongly predictive of pathological complete response (pCR) only in tumours receiving atezolizumab
1
4
17
Congratulations
@FAndreMD
!!
To be successful, research requires envisioning the future.
Repeating the same things will provide the same results.
Thank you for your outstanding contribution to the future of breast cancer research.
@AACR
@BCRFcure
@SABCSSanAntonio
#SABCS21
Join us in congratulating BCRF investigator
@FAndreMD
, who receives the
@AACR
Outstanding Investigator Award for Breast Cancer Research supported by BCRF today at
#SABCS21
!
@SABCSSanAntonio
@GustaveRoussy
#bcsm
2
8
100
1
5
17
#ORR
not a good
#SurrogateEndpoint
for OS in
#ImmuneCheckpoint
inhibitor trials.
Not surprising: duration of response is not captured by enumeration of responses.
Quality instead of quantity, and tail instead of median are key!
0
2
17